Abstract
Researchers have deciphered how a promising cancer drug acts like a smart bomb, homing in on only a very narrow range of its potential targets in the cell. The compound, known as STI-571, has shown remarkable success in early clinical trials on patients with chronic myelogenous leukemia. Now, in work reported on page 1938, scientists reveal just how the compound works--information that could aid in the design of similar cancer therapies.
MeSH terms
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / therapeutic use*
-
Benzamides
-
Catalytic Domain / drug effects
-
Clinical Trials as Topic
-
Enzyme Activation / drug effects
-
Enzyme Inhibitors / therapeutic use
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
-
Piperazines*
-
Protein Conformation
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Protein-Tyrosine Kinases / chemistry
-
Proto-Oncogene Proteins c-abl / antagonists & inhibitors*
-
Pyrimidines / chemistry
-
Pyrimidines / therapeutic use*
Substances
-
Antineoplastic Agents
-
Benzamides
-
Enzyme Inhibitors
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate
-
Protein-Tyrosine Kinases
-
Proto-Oncogene Proteins c-abl